Dermatologists treat more than 3,000 conditions, but not all of them receive equal attention. In this Next Steps in Derm video interview, in partnership with the ODAC Dermatology Conference, ODAC Conference Co-Chair Adam Friedman, MD, FAAD, addresses common, yet overlooked skin conditions, most of which do not have FDA-approved therapies. Watch and learn tips for the creative management of lichen planus and what treatments are on the horizon. Find out the role of oral steroids and off-label therapies in bullous pemphigoid. Hear Dr. Friedman’s approach and practical advice in treating warts. Plus catch how to sensibly use anti-fungals when treating dermatophyte infections.
Further Reading
If you want to read more about these four skin conditions, check out the following articles published in the Journal of Drugs in Dermatology:
Oral Lichen Planus Successfully Treated With Upadacitinib
ABSTRACT
With the rise of Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) inhibitor use in dermatologic conditions, there has been increasing hope in treating extensive and difficult-to-treat inflammatory cutaneous conditions. Today we report a case of oral lichen planus successfully treated with an oral JAK1 inhibitor, upadacitinib. This case had been unresponsive by several standard methods but responded with 70% improvement within 1 month when treated with upadacitinib.
The Current Landscape of Treatment of Warts
ABSTRACT
Warts have bothered people since the early Greek and Roman empires. For centuries, people have studied causes of and treatments for these irritating tumors. In recent history, treatments have stagnated. Warts are caused by non-enveloped, circular, double-stranded DNA human papillomavirus (HPV). Most infections are subclinical, but clinically relevant disease ranges from warts to invasive carcinoma. Two-thirds of warts resolve spontaneously within 2 years, meaning that the stakes for treatments are high. Successful therapies need to have high resolution, few side effects, and act fast. The lack of radical antiviral HPV treatment represents a significant care gap. Although common warts are generally due to low-risk HPV strains, coinfection with higher-risk variants is not uncommon.
Did you enjoy this video interview? Find more here.